Leading CROs unify trial data and processes for greater visibility and speed
BARCELONA, Spain, Oct. 17, 2022 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) have selected Veeva Vault CTMS to offer faster and more efficient assays to sponsors, which includes four of the top six global CROs. These global leaders – Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc. and Syneos Health – are unifying the clinic on a single platform by expanding their use of Veeva Vault Clinical Suite from Vault eTMF to now include Vault CTMS.
Also selected by over 120 sponsors, including 9 of the top 20 pharmaceutical companies, Vault CTMS has quickly become the industry’s leading clinical trial management solution. As CROs increasingly standardize on Vault CTMS, they can support sponsors’ preference for Veeva Vault while streamlining studio operations for more efficient execution.
Vault CTMS provides a comprehensive view of trial metrics so CROs can better manage study performance and increase transparency to sponsors. Sponsors and CROs using Vault CTMS work on a consistent industry-standard platform that facilitates collaboration and studio information sharing for real-time visibility across the studio portfolio.
“Veeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs,” said Henry Galio, Vice President of Veeva Vault CTMS. “As more companies advance trial operations with Veeva, sponsors, CROs and sites can work more closely together to drive faster study endpoints and accelerate trial enrollment of subjects.”
Vault CTMS is part of the Veeva Vault Clinical Operations Suite, enabling companies to share information and documents across eTMF, CTMS, payments, study commissioning, and study training to improve collaboration and execution throughout the clinical lifecycle. studio life.
Additional Information For more information about Veeva Vault CTMS, visit: veeva.com/eu/CTMS Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems Veeva is the world leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world’s largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit the website veeva.com/eu.
Veeva Forward-Looking Statements This release contains forward-looking statements about Veeva’s products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update any such statements. There are numerous risks that may adversely affect our results, including the risks and uncertainties set forth in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here (on pages 39-40). a summary of risks that may affect our business), and in our subsequent filings with the SEC, which you can access at sec.gov.
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/40-cros-eligen-veeva-vault-ctms-para-dirigir-las-operaciones-de-los-ensayos-clinicos-301651238.html
